849767-19-7

Usage

Uses

Used in Pharmaceutical Industry:
Tert-butyl 4-hydroxy-3-(hydroxymethyl)piperidine-1-carboxylate is utilized as a pharmaceutical intermediate for its ability to modify the properties of certain drugs. It plays a crucial role in enhancing the stability and bioavailability of medications, thereby improving their overall effectiveness and safety.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, tert-butyl 4-hydroxy-3-(hydroxymethyl)piperidine-1-carboxylate is employed for the development of new pharmaceutical compounds. Its unique structure and properties make it a valuable component in the creation of innovative and potentially life-saving medications.

Upstream product

• 161491-24-3 methyl 1-tert-butoxycarbonyl-4-oxo-3-piperidinecarboxylate 
• 71486-53-8 methyl 4-oxo-3-piperidinecarboxylate hydrochloride 
• 98977-34-5 1-tert-butyl 3-ethyl 4-oxopiperidine-1,3-dicarboxylate 
• 1454-53-1 ethyl 1-benzyl-4-oxopiperidine-3-carboxylate hydrochloride 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1331775-94-0 4-[6-butyl-5-(4-cyclohexyloxyphenyl)pyridazin-3-yloxy]-3-methoxymethoxymethylpiperidine-1-carboxylic acid tert-butyl ester 
• 849767-21-1 tert-butyl 3-[[tert-butyl(dimethyl)silyl]oxymethyl]-4-oxo-piperidine-1-carboxylate 

Relevant academic research and scientific papers

CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF

Disclosed herein, inter alia, are compounds and methods of use thereof for the modulation of chemokine receptor activity.

MITOCHONDRIAL INHIBITORS FOR THE TREATMENT OF PROLIFERATION DISORDERS

The invention provides compounds of formula I or pharmaceutically acceptable salt, solvate or hydrate thereof (I) wherein ring A represents group A-I or A- II (A-I, A-II) A1, A2, A3, A4 represent independently C(R4aa) or N, wherein no more than one of A1, A2, A3, and A4 represents N; A5 represents C(R4b) or N; B1, B2, B3 and B4 represent independently C(R3) or N, wherein no more than two of B1, B2, B3 and B4 represent N; n is 1 or 2; and R1, R2, R3, R4a and R4aa and R4b are as defined in the claims, as well as methods of using the compounds to treat proliferation diseases, in particular cancer.

FUSED PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS

The invention relates to fused piperidine amides useful as inhibitors of ion channels for the treatment of pain. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

HEPATITIS B ANTIVIRAL AGENTS

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

PHENYL-HETEROARYL DERIVATIVES AND METHODS OF USE THEREOF

The present invention provides phenyl-heteroaryl derivatives of Formula (I) and pharmaceutically acceptable salts thereof. These compounds are useful in the treatment of RAGE-mediated diseases such as Alzheimer's Disease. The present invention further relates to methods for the preparation of compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising such compounds, and the use of such compounds and/or pharmaceutical compositions in treating RAGE-mediated diseases.

The synthesis of substituted bipiperidine amide compounds as CCR3 antagonists

Bipiperidine amide 1 has been identified as a CC chemokine receptor 3 (CCR3) antagonist. Optimization of its structure-activity relationship has resulted in the identification of cis (R,R)-4-[(3,4-dichlorophenyl)methyl]-3- hydroxymethyl-1′(6-quinolinylcar

Piperdine derivatives useful as CCR3 antagonists

The use of CCR3 antagonists of the formula I or a pharmaceutically acceptable salt thereof for the treatment of asthma is disclosed, as well as novel compounds of the formula II, pharmaceutical compositions comprising them, and their use in the treatment